Table 3.
Abscess | Cellulitis | Wound | ||||
By infection typed | Daptomycin | Vancomycin | Daptomycin | Vancomycin | Daptomycin | Vancomycin |
(n = 40) | (n = 42) | (n = 54) | (n = 44) | (n = 17) | (n = 16) | |
IRLOS, hours, mean (SD) | 83.8 (53.8) | 102.1 (75.4) | 97.3 (61.5) | 80.2 (43.5) | 94.4 (63.4) | 109.0 (59.0) |
Total LOS, hours, mean (SD) | 94.8 (102.2) | 105.6 (75.2) | 101.7 (64.4) | 85.1 (56.6) | 103.0 (58.9) | 139.3 (94.3) |
Total inpatient cost, 2012 US$, mean (SD)a | 9515 (8501) | 9432 (5955) | 9871 (5805) | 7415 (4750) | 9814 (5927) | 13,101 (7025) |
Staphylococcus aureus e | MRSA | MSSA | ||||
By pathogen | Daptomycin | Vancomycin | Daptomycin | Vancomycin | Daptomycin | Vancomycin |
(n = 58) | (n = 43) | (n = 39) | (n = 27) | (n = 14) | (n = 10) | |
IRLOS, hours, mean (SD) | 98.4 (64.5) | 101.2 (69.4) | 98.5 (67.0) | 85.9 (51.8) | 84.5 (43.6) | 136.2 (95.5) |
Total LOS, hours, mean (SD) | 109.0 (95.9) | 105.4 (69.3) | 111.3 (108.5) | 92.3 (53.7) | 93.0 (54.2) | 136.2 (95.5) |
Total inpatient cost, 2012 US$, mean (SD)a | 10,508 (8109) | 9604 (5691) | 10,692 (9171) | 8854 (4119) | 8967 (4084) | 11,308 (8345) |
IRLOS infection-related length of stay, LOS length of stay, MRSA methicillin-resistant Staphylococcus aureus, MSSA methicillin-susceptible Staphylococcus aureus, SD standard deviation, WAC wholesale acquisition cost
aMultivariate analysis sample of 115 daptomycin and 106 vancomycin patients
bWAC cost estimates using “waste” algorithm
cThe P value was nonsignificant for all comparisons between daptomycin and vancomycin
dFour daptomycin and four vancomycin patients had other infection types
eIncludes known S. aureus infection for those patients with a culture; please note 5 daptomycin and 6 vancomycin patients were dropped from the MRSA/MSSA subgroup analyses mostly due to missing data